Center of Biomedical Research Excellence in Pharmaceutical Research and Innovation

药物研究与创新卓越生物医学研究中心

• 批准号: 10112923
• 负责人: Jon Scott Thorson
• 金额: $ 226.01万
• 依托单位: UNIVERSITY OF KENTUCKY
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-03-01 至 2025-01-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10112923
• 关键词: Address; Area; Biology; Biomedical Research; Cardiovascular Diseases; Centers of Research Excellence; Chemicals; Clinical; Collaborations; Communicable Diseases; Communication; Core Facility; Development; Devices; Discipline; Disease; Education; Environment; Faculty; Fostering; Funding; Gap Junctions; Goals; Health; Infrastructure; Kentucky; Malignant Neoplasms; Mentors; Mentorship; Modeling; Molecular Medicine; Organic Synthesis; Outcome; Pharmacologic Substance; Pharmacy facility; Phase; Pilot Projects; Research; Research Personnel; Research Project Grants; Research Support; Science; Scientist; Testing; Therapeutic; Translational Research; Translations; Universities; Validation; career development; clinical application; college; experience; faculty research; innovation; interdisciplinary collaboration; interest; multidisciplinary; pre-clinical; pre-clinical research; prevent; tool

PROJECT SUMMARY/ABSTRACT - OVERALL We propose to establish a Center of Biomedical Research Excellence (COBRE) in Pharmaceutical Research and Innovation at the University of Kentucky (UK). CPRI will serve as a comprehensive multidisciplinary center focused on translational chemical biology [the nexus of chemical biology (the application of chemical biology principles to develop validated probe/models to advance our understanding of biology) and pharmaceutical science (the application of pharmaceutical principles to advance leads/materials/devices that address unmet clinical needs)]. The COBRE will leverage and develop unique translational chemical biology research support infrastructure/expertise to facilitate junior faculty mentorship and career development, innovative biomedical research probe/tool/model/materials development and validation, and the early advancement of potential ‘translatable’ assets. Key COBRE infrastructure to be developed and implemented in Phase I includes the CPRI Administrative Core and two research support cores (the Translational Core and the Computational Core) and the COBRE will also further develop and leverage the COBRE for Molecular Medicine’s Organic Synthesis Core to support CPRI junior faculty projects/pilots. CPRI will initially support four outstanding junior investigators working in three therapeutic areas (cancer, infectious disease and cardiovascular disease). Our overarching hypothesis is that CPRI’s translational chemical biology focus presents a distinctly unique UK platform to: i) engage, integrate and mentor junior faculty from a broad range of fundamental, applied and clinical disciplines; ii) facilitate the development of new impactful probes/tools/models and advance innovative transdisciplinary research; and iii) bridge the gap between basic academic research discoveries and commercial/clinical application via education, mentorship and key support infrastructure. CPRI’s distinct focus on translational chemical biology and early translation fills a notable preclinical research gap for many of UK’s exceptional research centers strategically focused on understanding, treating and preventing the major diseases that contribute to Kentucky’s disproportionate health challenges. Anticipated COBRE outcomes include an increase in the number and diversity of UK junior faculty engaged in translational chemical biology research and better-prepared to develop and employ innovative biomedical probes/tools/models/materials, new sustainable UK translational chemical biology research support infrastructure and capabilities, an increase in the number of UK junior faculty with independent research funding, and a boost in the number potentially ‘translatable’ UK preclinical assets.

项目摘要/摘要--总体 我们建议成立生物医学卓越研究中心(COBRE)进行药物研究 肯塔基大学(英国)的创新与研究。CPRI将作为一个综合性的多学科中心 侧重于翻译化学生物学[化学生物学的纽带(化学生物学的应用 开发有效的探针/模型以促进我们对生物学的理解的原则)和药学 科学(将药学原理应用于解决未满足的问题的先进引线/材料/装置 临床需求)]。科布雷将利用和开发独特的翻译化学生物学研究支持 基础设施/专业知识，以促进初级教师指导和职业发展，创新的生物医学 研究探索/工具/模型/材料的开发和验证，以及潜力的早期进展 “可转换”资产。将在第一阶段开发和实施的主要Cobre基础设施包括CPRI 行政核心和两个研究支助核心(翻译核心和计算核心)和 科布雷还将进一步开发和利用分子医学的有机合成核心科布雷 支持CPRI初级教员项目/试点。CPRI将初步支持四名优秀的初级调查人员 在三个治疗领域(癌症、传染病和心血管疾病)工作。 我们的总体假设是，CPRI的翻译化学生物学重点呈现了一个明显独特的 英国平台：i)吸引、整合和指导来自广泛的基础、应用和 临床学科；ii)促进新的有效探头/工具/模型的开发并推进创新 跨学科研究；以及iii)弥合基础学术研究发现和 通过教育、指导和关键支持基础设施实现商业/临床应用。CPRI的鲜明重点 关于翻译化学生物学和早期翻译的研究填补了许多英国的临床前研究空白 特殊的研究中心战略性地专注于了解、治疗和预防重大疾病 这导致了肯塔基州不成比例的健康挑战。预期的Cobre结果包括 英国从事翻译化学生物学研究的初级教员的数量和多样性的增加 更好地准备开发和使用创新的生物医学探头/工具/模型/材料，新的可持续发展 英国翻译化学生物学研究支持基础设施和能力，数量增加 英国初级教员获得独立研究资金，并增加了潜在的可翻译英国教师的数量 临床前资产。